Aim: The aim of this study is to compare different aspects of closeness in the relation of mothers towards their adult sons suffering from schizophrenia or drug addiction. Werner and Green (1996), in analyzing the concept of"enmeshment", distinguish between two independent dimensions of closeness: 1) pathological--intrusiveness and 2) positive--closeness-caregiving. Intrusiveness refers to a high level of separation anxiety, projective mystification, emotional inter-reactivity and possessiveness. Closeness-caregiving is associated with warmth, spending time together, nurturance, physical intimacy and consistency.
Method: Mothers were divided into three groups according to the diagnosis of their sons: 1) schizophrenia, 2) drug addiction, 3) control group. Subjects completed the California Inventory for Family Assessment. Its scales showed acceptable reliability and validity.
Results: Mothers perceive their interaction with drug addicted sons as less close, more aggressive and unpredictable than mothers from the control group. Unexpectedly mothers of patients with schizophrenia describe relationships with their sons in a more positive way than mothers from the control and drug addiction group (warmer, less possessive, less intense separation anxiety and less aggression). Additionally, they describe their relationships as less open and striving to avoid conflicts.
Conclusions: Further studies should be conducted to verify if mothers of sons with schizophrenia describe their relations in positive terms as a result of the following: 1) self-protective bias, 2) a low level of openness or 3) good coping.
Download full-text PDF |
Source |
---|
Cells
January 2025
Department of Physiology, College of Medicine, Hallym University, Chuncheon 24252, Republic of Korea.
Phosphodiesterase (PDE) enzymes regulate intracellular signaling pathways crucial for brain development and the pathophysiology of neurological disorders. Among the 11 PDE subtypes, PDE4 and PDE5 are particularly significant due to their regulation of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling, respectively, which are vital for learning, memory, and neuroprotection. This review synthesizes current evidence on the roles of PDE4 and PDE5 in neurological health and disease, focusing on their regulation of second messenger pathways and their implications for brain function.
View Article and Find Full Text PDFJ Orthop Surg Res
January 2025
Guizhou Medical University, Guiyang, China.
Background: Ferroptosis is an iron-dependent regulatory cell death, which plays an essential role in bone loss. This study investigated whether the mechanism of risperidone (RIS)-induced bone loss is related to ferroptosis.
Methods: The schizophrenia mice were induced by administering MK-801.
BMC Psychiatry
January 2025
Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru.
Background: Schizophrenia is a complex psychiatric disorder, and in patients treated with clozapine, it may induce or exacerbate obsessive-compulsive symptoms (OCS), which negatively affect patients' quality of life, functionality and treatment adherence. Despite its clinical relevance, the reported prevalence and characteristics of clozapine associated OCS vary widely, limiting effective management.
Objective: This scoping review synthesizes evidence on the prevalence of OCS in patients with schizophrenia treated with clozapine and explores treatment characteristics (types, severity, dose, and time to onset/exacerbation).
Lancet Psychiatry
February 2025
Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland; Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden; Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden; Neuroscience Center, University of Helsinki, Helsinki, Finland.
Background: The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different treatment strategies used before and after the first relapse, and their associations with subsequent relapse risk.
Methods: In this population-based cohort study, we enrolled individuals (aged ≤45 years) with first-episode schizophrenia who were hospitalised and subsequently relapsed between 1996 and 2014 from the nationwide Finnish Hospital Discharge Register.
F1000Res
January 2025
German Center for Mental Health (DZPG), partner site München/Augsburg, Munich, Germany.
Background: Muscarinic receptor agonism and positive allosteric modulation is a promising mechanism of action for treating psychosis, not present in most D2R-blocking antipsychotics. Xanomeline, an M1/M4-preferring agonist, has shown efficacy in late-stage clinical trials, with more compounds being investigated. Therefore, we aim to synthesize evidence on the preclinical efficacy of muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis to provide unique insights and evidence-based information to guide drug development.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!